STOCK TITAN

[Form 4] Avantor, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Avantor (AVTR) insider filing: The company’s EVP, Bioscience Production reported a Form 4 transaction on 10/02/2025. The filing shows 1,264 shares of common stock were withheld by the issuer at $13.77 under code F, which reflects shares retained to satisfy tax withholding in connection with RSU vesting. Following this administrative withholding, the reporting person directly holds 235,684 shares.

Filing interno di Avantor (AVTR): Il vicepresidente esecutivo della divisione Bioscience Production ha riportato una transazione Form 4 il 02/10/2025. La dichiarazione indica che 1.264 azioni ordinarie sono state trattenute dall’emittente al prezzo di 13,77 USD, secondo il codice F, azioni trattenute per soddisfare la ritenuta fiscale in relazione al vesting degli RSU. Dopo questa trattenuta amministrativa, la persona indicata detiene direttamente 235.684 azioni.

Presentación interna de Avantor (AVTR): El vicepresidente ejecutivo de Bioscience Production comunicó una transacción Form 4 el 02/10/2025. La declaración muestra que 1.264 acciones comunes fueron retenidas por el emisor a 13,77 USD bajo el código F, lo que refleja acciones retenidas para satisfacer la retención de impuestos relacionada con el vesting de las RSU. Tras esta retención administrativa, la persona informante posee directamente 235.684 acciones.

Avantor(AVTR) 내부공시: 회사의 바이오사이언스 프로덕션 부문 EVP가 2025년 10월 2일 Form 4 거래를 보고했습니다. 공시는 발행인이 주당 13.77달러의 코드 F에 따라 1,264주를 보유하지 않은 대신 공제했음을 보여주며, 이는 RSU 가속 vesting과 관련된 세금 원천징수를 충당하기 위해 보유한 주식에 반영됩니다. 이 행정적 원천징수 후, 보고자는 직접적으로 235,684주를 보유하게 됩니다.

Dépôt interne d'Avantor (AVTR): Le vice-président exécutif de Biosciences Production a signalé une transaction Form 4 le 02/10/2025. Le dossier indique que 1 264 actions ordinaires ont été retenues par l’émetteur à 13,77 USD dans le cadre du code F, ce qui reflète des actions retenues pour satisfaire l’imposition liée au vesting des RSU. Après cette retenue administrative, la personne déclarant détient directement 235 684 actions.

Interne Meldung von Avantor (AVTR): Der EVP für Bioscience Production meldete am 02.10.2025 eine Form-4-Transaktion. Die Meldung weist darauf hin, dass vom Emittenten 1.264 Stammaktien zu 13,77 USD unter Code F einbehalten wurden, was Aktien widerspiegelt, die zur Begleichung der Steuerrückbehalte im Zusammenhang mit der RSU-Vesting einbehalten wurden. Nach diesem administrativen Einbehalt hält die meldepflichtige Person direkt 235.684 Aktien.

تقرير داخلي لAvantor (AVTR): أفاد نائب الرئيس التنفيذي للإنتاج الحيوي (Bioscience Production) بصفته فرداً بإدراج Form 4 في 02/10/2025. يبيّن الملف أن 1,264 سهماً عائداً إلى الأسهم العادية تم حجزها من قبل المصدر بسعر 13.77 دولار تحت الرمز F، وهذا يعكس أسهماً محتجَزة لتلبية استقطاع الضرائب المرتبط بـ vesting RSU. وبعد هذا الاستقطاع الإداري، يمتلك الشخص المبلّغ عنه مباشرة 235,684 سهماً.

Avantor (AVTR) 内部披露: 公司的生物科学生产部门执行副总裁在 2025/10/02 报告了一笔 Form 4 交易。披露显示发行人按代码 F 以 13.77 美元的价格扣留了 1,264 股普通股,用于与 RSU 授与相关的税收代扣。完成此项行政扣留后,申报人直接持有 235,684 股。

Positive
  • None.
Negative
  • None.

Filing interno di Avantor (AVTR): Il vicepresidente esecutivo della divisione Bioscience Production ha riportato una transazione Form 4 il 02/10/2025. La dichiarazione indica che 1.264 azioni ordinarie sono state trattenute dall’emittente al prezzo di 13,77 USD, secondo il codice F, azioni trattenute per soddisfare la ritenuta fiscale in relazione al vesting degli RSU. Dopo questa trattenuta amministrativa, la persona indicata detiene direttamente 235.684 azioni.

Presentación interna de Avantor (AVTR): El vicepresidente ejecutivo de Bioscience Production comunicó una transacción Form 4 el 02/10/2025. La declaración muestra que 1.264 acciones comunes fueron retenidas por el emisor a 13,77 USD bajo el código F, lo que refleja acciones retenidas para satisfacer la retención de impuestos relacionada con el vesting de las RSU. Tras esta retención administrativa, la persona informante posee directamente 235.684 acciones.

Avantor(AVTR) 내부공시: 회사의 바이오사이언스 프로덕션 부문 EVP가 2025년 10월 2일 Form 4 거래를 보고했습니다. 공시는 발행인이 주당 13.77달러의 코드 F에 따라 1,264주를 보유하지 않은 대신 공제했음을 보여주며, 이는 RSU 가속 vesting과 관련된 세금 원천징수를 충당하기 위해 보유한 주식에 반영됩니다. 이 행정적 원천징수 후, 보고자는 직접적으로 235,684주를 보유하게 됩니다.

Dépôt interne d'Avantor (AVTR): Le vice-président exécutif de Biosciences Production a signalé une transaction Form 4 le 02/10/2025. Le dossier indique que 1 264 actions ordinaires ont été retenues par l’émetteur à 13,77 USD dans le cadre du code F, ce qui reflète des actions retenues pour satisfaire l’imposition liée au vesting des RSU. Après cette retenue administrative, la personne déclarant détient directement 235 684 actions.

Interne Meldung von Avantor (AVTR): Der EVP für Bioscience Production meldete am 02.10.2025 eine Form-4-Transaktion. Die Meldung weist darauf hin, dass vom Emittenten 1.264 Stammaktien zu 13,77 USD unter Code F einbehalten wurden, was Aktien widerspiegelt, die zur Begleichung der Steuerrückbehalte im Zusammenhang mit der RSU-Vesting einbehalten wurden. Nach diesem administrativen Einbehalt hält die meldepflichtige Person direkt 235.684 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gourdier Benoit

(Last) (First) (Middle)
RADNOR CORPORATE CENTER, BUILDING ONE,
SUITE 200, 100 MATSONFORD ROAD

(Street)
RADNOR PA 19087

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Avantor, Inc. [ AVTR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Bioscience Production
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 F(1) 1,264 D $13.77 235,684 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
Remarks:
/s/ Scott Baker, as Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Avantor (AVTR) disclose in this Form 4?

An officer reported 1,264 shares withheld at $13.77 on 10/02/2025 to cover taxes upon RSU vesting (code F).

Who is the reporting person and their role at AVTR?

The reporting person is an officer, serving as EVP, Bioscience Production.

How many AVTR shares does the officer own after the transaction?

The reporting person directly owns 235,684 shares after the transaction.

What does transaction code F mean in this context?

Code F indicates shares were withheld by the issuer to satisfy tax withholding obligations related to RSU vesting.

Was this an open-market sale of AVTR shares?

No. The filing shows issuer share withholding for taxes tied to RSU vesting, not an open-market sale.

What was the per-share price used for the withholding?

The withholding was recorded at $13.77 per share.
Avantor

NYSE:AVTR

AVTR Rankings

AVTR Latest News

AVTR Latest SEC Filings

AVTR Stock Data

9.14B
657.64M
1.37%
106.68%
4.4%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
RADNOR